Lone Pine Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-1,529,618
Closed -$186M 29
2023
Q2
$186M Hold
1,529,618
1.7% 25
2023
Q1
$235M Buy
1,529,618
+177,100
+13% +$29.2M 2.17% 22
2022
Q4
$243M Buy
+1,352,518
New +$221M 2.32% 18
2021
Q4
Sell
-3,316,199
Closed -$1.28B 38
2021
Q3
$1.28B Sell
3,316,199
-674,698
-17% -$249M 4.3% 9
2021
Q2
$938M Buy
+3,990,897
New +$713M 3.02% 16

Other funds holding MRNA

Lone Pine Capital's MRNA Position: Q3 2023 in Review

Lone Pine Capital sold out of Moderna (MRNA) in Q3 2023, closing a stake of 1,529,618 shares — an estimated $186M sold.

Lone Pine Capital first reported a position in MRNA in Q2 2021 and held it in 5 quarters. The position peaked at $1.28B in Q3 2021. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Lone Pine Capital reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Lone Pine Capital sold 1,529,618 Moderna shares in Q3 2023, an estimated $186M.
  • Lone Pine Capital first reported a position in Moderna in Q2 2021 and held it in 5 quarters.
  • Lone Pine Capital's Moderna position peaked at $1.28B in Q3 2021.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Lone Pine Capital's 13F filing for Q3 2023, filed 14 Nov 2023.